N4 Pharma Plc (LON:N4P – Get Free Report) shares shot up 4.7% on Thursday . The stock traded as high as GBX 0.45 ($0.01) and last traded at GBX 0.45 ($0.01). 717,440 shares changed hands during trading, a decline of 68% from the average session volume of 2,219,572 shares. The stock had previously closed at GBX 0.43 ($0.01).
N4 Pharma Stock Up 5.9 %
The firm’s fifty day moving average price is GBX 0.54 and its two-hundred day moving average price is GBX 0.60. The stock has a market capitalization of £1.94 million, a PE ratio of -1.30 and a beta of -0.37.
About N4 Pharma
RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.
N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners.
N4 Pharma’s lead programme, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.
See Also
- Five stocks we like better than N4 Pharma
- What Are Dividends? Buy the Best Dividend Stocks
- Archer Aviation’s Africa Deal Could Boost ACHR Stock
- Golden Cross Stocks: Pattern, Examples and Charts
- Are Short Sellers Wrong About These 3 Semiconductor Stocks?
- What Does Downgrade Mean in Investing?
- Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?
Receive News & Ratings for N4 Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for N4 Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
